Trichomegaly of the eyelashes following treatment with cetuximab

Bouché, Olivier; Brixi-Benmansour, Hedia; Bertin, Aline; Perceau, G.; Lagarde, Stanislas

doi:10.1093/annonc/mdi300

Cited by 80 publications

(60 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similarly, the patient of the current study presented an activating mutation (L858R) in exon 21 and experienced a moderate rash on her face, chest and back; however, the patient did not present similar progression-free survival benefits. Considering the present case along with similar cases previously reported in the literature (5,16,25) led to several interesting observations. Patients who manifested trichomegaly also exhibited a poor progression-free survival (3-7 months), and disease progression occurred after 1-3 months of trichomegaly.…”

Section: A B C Dsupporting

confidence: 85%

Eyelash trichomegaly following treatment with erlotinib in a non-small cell lung cancer patient: A case report and literature review

et al. 2015

View full text Add to dashboard Cite

Abstract. Inhibitors of epidermal growth factor receptor (EGFR), including tyrosine kinase inhibitors (TKIs), present significant clinical benefits in the treatment of non-small cell lung cancer (NSCLC), particularly in patients with an EGFR mutation. However, TKI treatment also results in unwanted cutaneous toxic side effects, such as a skin rash. Eyelash trichomegaly is rarely reported as a side effect; however, it causes cosmetic issues or eyeball irritation in patients, which may result in the early termination of TKI treatment. Therefore, although TKI-induced eyelash trichomegaly is rare, it should be considered carefully by lung cancer physicians. The present study reported a case of erlotinib-induced eyelash trichomegaly in a 65-year-old Chinese female patient suffering from NSCLC with an EGFR mutation. To the best of our knowledge, this is the first reported case of erlotinib-induced trichomegaly in a Chinese patient.

show abstract

Section: A B C Dsupporting

confidence: 85%

Eyelash trichomegaly following treatment with erlotinib in a non-small cell lung cancer patient: A case report and literature review

et al. 2015

View full text Add to dashboard Cite

show abstract

“…[85][86][87] These effects are not surprising given the role of EGFR family members in the cornea healing process. 88,89 The presence of rash as a positive predictor of improved outcome with EGFR inhibitors including cetuximab was suggested initially in studies of cetuximab in HNSCC and colorectal cancer.…”

Section: Tolerabilitymentioning

confidence: 97%

The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer

Tejani

Cohen²,

Mehra

2010

BTT

View full text Add to dashboard Cite

Recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC) continues to be a source of significant morbidity and mortality worldwide. Agents that target the epidermal growth factor receptor (EGFR) have demonstrated beneficial effects in this setting. Cetuximab, a monoclonal antibody against the EGFR, improves locoregional control and overall survival when used as a radiation sensitizer in patients with locoregionally advanced HNSCC undergoing definitive radiation therapy with curative intent. Cetuximab is also active as monotherapy in patients whose cancer has progressed on platinum-containing therapy. In the first-line setting for incurable HNSCC, cetuximab added to platinum-based chemotherapy significantly improves overall survival compared with standard chemotherapy alone. These positive results have had a significant impact on the standard of care for advanced HNSCC. In this review, we will discuss the mechanism of action, clinical data and common toxicities that pertain to the use of cetuximab in the treatment of advanced incurable HNSCC.

show abstract

“…Most cases are mild to moderate but severe in 5% to 20% of patients [6,7,34,35,54]. Prophylactic treatment with systemic tetracyclines reduces the severity of skin reactions but not the incidence of rash [55][56][57].Other dermatological reactions are xerosis, fissures of palm and foot, paronychia and extensive growth of both eyelashes and eyebrows [53,54,58,59], but these side-effects are primarily seen after many months of exposure to anti-EGFR therapy.…”

Section: Toxicity Of Anti-egfr Therapymentioning

confidence: 99%